When viewing this topic in a different language, you may notice some differences in the way the content is structured, but it still reflects the latest evidence-based guidance.

Menopause

Последний просмотренный: 12 Oct 2025
Last updated: 04 Dec 2024

Резюме

Определение

Анамнез и осмотр

Ключевые диагностические факторы

  • amenorrhea
  • irregular menstrual cycle
  • hot flashes and night sweats
  • vaginal symptoms
  • mood changes
Полная информация

Другие диагностические факторы

  • sleep disturbance
  • mild memory impairment
  • heavy menstrual bleeding
Полная информация

Факторы риска

  • age 40 to 60 years
  • cancer treatment
  • smoking
  • ovarian surgery
  • mother's age at menopause
Полная информация

Диагностические исследования

Исследования, которые показаны в первую очередь

  • pregnancy test
Полная информация

Исследования, проведение которых нужно рассмотреть

  • follicle-stimulating hormone (FSH)
  • serum estradiol
Полная информация

Алгоритм лечения

Острый

initial presentation with mild vasomotor symptoms

ПРОДОЛЖЕНИЕ

women with a uterus, moderate to severe hot flashes, with/without reduced libido

women without a uterus or with levonorgestrel-releasing intrauterine device fitted in the last 5 years, moderate to severe hot flashes, with/without reduced libido

urogenital atrophy only

urinary stress incontinence only

Составители

Авторы

Heather Currie, MB BS, FRCOG, DRCOG, MRCGP

Clinical Director Women and Sexual Health

NHS Dumfries and Galloway

Dumfries and Galloway Royal Infirmary

Scotland

UK

Раскрытие информации

HC declares that she has no competing interests.

Haitham Hamoda, MBChB, MD, FRCO

Consultant Gynaecologist

Clinical Lead for Menopause Service

King's College Hospital NHS Trust

London

UK

Раскрытие информации

HH declares that he has no competing interests.

Bradford W. Fenton, MD, PhD, FACOG

Independence Park Medical Services

Anchorage

AK

Раскрытие информации

BWF declares that he has no competing interests.

Выражение благодарностей

Dr Heather Currie, Dr Haitham Hamoda, and Dr Bradford W. Fenton would like to gratefully acknowledge Dr Rebekah Wang-Cheng, a previous contributor to this topic.

Раскрытие информации

RWC declares that she has no competing interests.

Рецензенты

Nan Gillespie O’Connell, MD

Assistant Professor

Department of Obstetrics and Gynecology

Virginia Commonwealth University

Richmond

VA

Раскрытие информации

NGOC declares that she has no competing interests.

Carolyn Simpkins, MD, PhD

Internist

Daniel Island

SC

Раскрытие информации

CS declares that she has no competing interests.

Edward Morris, MD

Consultant

Honorary Senior Lecturer and Clinical Director

Department of Obstetrics and Gynaecology

Norfolk and Norwich University Hospital

Norwich

UK

Раскрытие информации

EM declares that he has no competing interests.

Michelle Warren, MD

Professor of Medicine and Obstetrics & Gynecology

Obstetrics and Gynecology

Columbia University in New York Medical Center

New York

NY

Disclosures

MW has received research funding from Ferring and Pfizer Wyeth; has acted as an advisory board consultant for Pfizer Wyeth, QuatRx, and Yoplait; and is on the speakers' bureau of Amgen, Upsher Smith, and Warner Chilcott. MW is also an author of a reference cited in this topic.

Peer reviewer acknowledgements

BMJ Best Practice topics are updated on a rolling basis in line with developments in evidence and guidance. The peer reviewers listed here have reviewed the content at least once during the history of the topic.

Disclosures

Peer reviewer affiliations and disclosures pertain to the time of the review.

References

Our in-house evidence and editorial teams collaborate with international expert contributors and peer reviewers to ensure that we provide access to the most clinically relevant information possible.

Key articles

Barnabei VM, Cochrane BB, Aragaki AK, et al. Menopausal symptoms and treatment-related effects of estrogen and progestin in the Women's Health Initiative. Obstet Gynecol. 2005 May;105(5 Pt 1):1063-73. Abstract

Avis NE, Crawford SL, Greendale G, et al. Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Intern Med. 2015 Apr;175(4):531-9.Full text  Abstract

North American Menopause Society. Management of osteoporosis in postmenopausal women: the 2021 position statement of The North American Menopause Society. Menopause. 2021 Sep 1;28(9):973-97. Abstract

The North American Menopause Society Advisory Panel. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022 Jul 1;29(7):767-94. Abstract

Marjoribanks J, Farquhar C, Roberts H, et al. Long-term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst Rev. 2017 Jan 17;(1):CD004143.Full text  Abstract

Manson JE, Aragaki AK, Rossouw JE, et al. Menopausal hormone therapy and long-term all-cause and cause-specific mortality: the women's health initiative randomized trials. JAMA. 2017 Sep 12;318(10):927-38. Abstract

Reference articles

A full list of sources referenced in this topic is available to users with access to all of BMJ Best Practice.
  • Differentials

    • Pregnancy
    • Polycystic ovary syndrome
    • Hyperthyroidism
    More Differentials
  • Guidelines

    • Nonhormone therapy position statement
    • Optimising the menopause transition
    More Guidelines
  • Patient information

    Menopause: what is it?

    Menopausal symptoms: what are the treatment options?

    More Patient information
  • padlock-lockedLog in or subscribe to access all of BMJ Best Practice

Use of this content is subject to our disclaimer